Cargando…

Effectiveness of aprepitant in post‐acute COVID19 syndrome

This is the first case of a patient taking aprepitant for a post‐acute COVID‐19 syndrome. This case may encourage researchers to look for the evidence for the efficacy and safety of a neurokinin 1 receptor antagonist in this frequent syndrome.

Detalles Bibliográficos
Autores principales:	Reinoso‐Arija, Rocío, López‐Ramírez, Cecilia, Jimenez‐Ruiz, José Antonio, López‐Campos, José Luis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449093/ https://www.ncbi.nlm.nih.gov/pubmed/34567551 http://dx.doi.org/10.1002/ccr3.4646

Ejemplares similares

Step-Up and Step-Down Treatment Approaches for COPD: A Holistic View of Progressive Therapies
por: López-Campos, Jose Luis, et al.
Publicado: (2021)

Exploring Current Concepts and Challenges in the Identification and Management of Early-Stage COPD
por: Doña, Esperanza, et al.
Publicado: (2023)

Chronic obstructive pulmonary disease mortality trends in Spain, 1980-2020
por: Cayuela, Lucia, et al.
Publicado: (2023)

Dysfunction in the Cystic Fibrosis Transmembrane Regulator in Chronic Obstructive Pulmonary Disease as a Potential Target for Personalised Medicine
por: Carrasco-Hernández, Laura, et al.
Publicado: (2021)

Methodologies for the Determination of Blood Alpha1 Antitrypsin Levels: A Systematic Review
por: Ruiz-Duque, Borja, et al.
Publicado: (2021)

The interaction of ifosfamide and aprepitant in gynecologic malignancies()
por: Shindorf, Mackenzie L., et al.
Publicado: (2013)

Evaluation of Different Doses in Inhaled Therapy: A Comprehensive Analysis
por: Lopez-Campos, José Luis, et al.
Publicado: (2023)

Emerging Role of Aprepitant in Cannabis Hyperemesis Syndrome
por: Parvataneni, Swetha, et al.
Publicado: (2019)

Resultados de la implementación de un programa de detección de casos de déficit de alfa-1 antitripsina en pacientes con EPOC
por: Reinoso-Arija, Rocío, et al.
Publicado: (2023)

A Comparative Study between Spanish and British SARS-CoV-2 Variants
por: Jimenez Ruiz, Jose A., et al.
Publicado: (2021)

Spike protein of SARS-CoV-2 Omicron variant: An in-silico study evaluating spike interactions and immune evasion
por: Jimenez Ruiz, Jose A., et al.
Publicado: (2022)

Acute Aortic Syndrome in a patient with COVID-19
por: Cunha, João Campos, et al.
Publicado: (2023)

Aprepitant for the Treatment of Chronic Refractory Pruritus
por: He, Alice, et al.
Publicado: (2017)

Post-Acute COVID-19 Symptoms, a Potential Link with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A 6-Month Survey in a Mexican Cohort
por: González-Hermosillo, J Antonio, et al.
Publicado: (2021)

Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study
por: Moreno-Pérez, Oscar, et al.
Publicado: (2021)

Treatment for Refractory Pruritus Using Oral Aprepitant
por: Huh, Joon Won, et al.
Publicado: (2016)

Aprepitant for the management of nausea with inpatient IV dihydroergotamine
por: Chou, Denise E., et al.
Publicado: (2016)

Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant
por: Olver, Ian, et al.
Publicado: (2007)

Preparation and Characterization of Nanosuspension of Aprepitant by H96 Process
por: Kalvakuntla, Sunethra, et al.
Publicado: (2016)

Influence of aprepitant on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits
por: Kura, Raghunandan Reddy, et al.
Publicado: (2018)

Characterization and Pharmacokinetic Study of Aprepitant Solid Dispersions with Soluplus(®)
por: Liu, Jinwen, et al.
Publicado: (2015)

Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects
por: Yang, Meng-Jie, et al.
Publicado: (2020)

Preparation and Characterization of Aprepitant Solid Dispersion with HPMCAS-LF
por: Liu, Jinwen, et al.
Publicado: (2022)

High-flow nasal cannula for Acute Respiratory Distress Syndrome (ARDS) due to COVID-19
por: Panadero, Carolina, et al.
Publicado: (2020)

Ifosfamide-induced Encephalopathy Precipitated by Aprepitant: A Rarely Manifested Side Effect of Drug Interaction
por: Kataria, Pritam Sureshchandra, et al.
Publicado: (2017)

Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature
por: Song, Johanna S., et al.
Publicado: (2017)

Aprepitant Sensitizes Acute Myeloid Leukemia Cells to the Cytotoxic Effects of Cytosine Arabinoside in vitro and in vivo
por: Wu, Hongzhang, et al.
Publicado: (2020)

Efficacy and Safety of Aprepitant in Allogeneic Hematopoietic Stem Cell Transplantation
por: Uchida, Mayako, et al.
Publicado: (2013)

In Vitro Biological Evaluation of Aprepitant Based (177)Lu-Radioconjugates
por: Halik, Paweł K., et al.
Publicado: (2022)

Clinical Observation of Gene Polymorphism of Olanzapine or Aprepitant in Prevention of CINV
por: Jin, Yilan, et al.
Publicado: (2021)

Need for Flexible Adjustment of the Treatment Schedule for Aprepitant Administration against Erlotinib-Induced Refractory Pruritus and Skin Rush
por: Seki, Nobuhiko, et al.
Publicado: (2019)

A patient with concurrent prurigo nodularis and squamous cell carcinomas of keratoacanthoma type: The role of aprepitant in diagnostic clarity
por: Jedlowski, Patrick M., et al.
Publicado: (2019)

Targeting the Neurokinin Receptor 1 with Aprepitant: A Novel Antipruritic Strategy
por: Ständer, Sonja, et al.
Publicado: (2010)

Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting
por: Chrisp, Paul
Publicado: (2007)

Effects of Aprepitant on the Pharmacokinetics of Controlled-Release Oral Oxycodone in Cancer Patients
por: Fujiwara, Yutaka, et al.
Publicado: (2014)

Two Cases of Fatal Encephalopathy Related to Ifosfamide: An Adverse Role of Aprepitant?
por: Séjourné, Alice, et al.
Publicado: (2014)

The efficacy of combination of ondansetron and aprepitant on preventing the radiotherapy-induced nausea and vomiting
por: Emami, Hamid, et al.
Publicado: (2015)

The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?
por: Muñoz, Miguel, et al.
Publicado: (2020)

OTHR-16. CONCURRENT USE OF APREPITANT AND IFOSFAMIDE IN PEDIATRIC CANCER PATIENTS
por: Winzent, Shelby, et al.
Publicado: (2020)

The Therapeutic Potential of Aprepitant in Glioblastoma Cancer Cells through Redox Modification
por: Rezaei, Soodabeh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vqa7gs67e2fjg7824dkf3c1irj